Phase I and II Studies with Lobaplatin

  • H. H. Fiebig


Cisplatin (Cis-diamminodichloro-platinum) (II) is widely used in cancer therapy. This agent has become the main component of regimens that cure patients with cancer of the testicle and produces high response rates in patients with small cell cancer of the lung, ovarian cancer, and bladder cancers (1–2). However, the toxicity is severe including intensive nausea and vomiting and renal toxicity. Furthermore, oto- and neurotoxicity (3) were observed especially during long term therapy. The side effects encouraged the development of analogues with a better therapeutic index. Cis-diamino-1,1-cyclobutane-dicarboxylato-platinum (Carboplatin) was selected from a large number of analogues developed by Harrap et al (4). In the clinic this compound demonstrated less emetic and no nephrotoxic effects. Myelosuppression, mainly thrombopenia, is the dose limiting toxicity of carboplatin. A cross resistance between Cisplatin and Carboplatin was shown in most tumor types. In bladder and testicular cancer Cisplatin has a higher activity than Carboplatin. In most other tumor types the spectrum of activity is similar (5).


Ovarian Cancer Bladder Cancer Esophageal Cancer Testicular Cancer Platinum Complex 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    L.H. Einhorn and J. Donahue. Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Inter Med 87:293 (1977).CrossRefGoogle Scholar
  2. 2.
    E. Wiltshaw and T. Kroner. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875, CACP) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 60:55 (1976).PubMedGoogle Scholar
  3. 3.
    M.S. Soloway. Cis-diamminedichloroplatinum(II) (DDP) in advanced bladder cancer. J Urol 120:716 (1978).PubMedGoogle Scholar
  4. 4.
    R. Canetta, K. Bragman, L. Smaldone, and M. Rozenzweig. Carboplatin: current status and future prospects. Cancer Treat Rev 15:17 (1988).CrossRefPubMedGoogle Scholar
  5. 5.
    K.R. Harrap, M. Jones, C.R. Wilkinson, H.McD. Clink, S. Sparrow, B.C.V. Mitchley, S. Clarke and A. Veasey. Antitumor, toxic and biochemical properties of cisplatin and eight other platinum complexes. In: “Cisplatin. Current status and new developments” A.W. Prestayko, S.T. Crooke and S.K. Carter eds Academic Press New York, London, Toronto, Sydney, San Francisco, 193 (1980)Google Scholar
  6. 6.
    R. Voegeli, W. Schumacher, J. Engel, J. Respondek, and P. Hilgard. D-19466 a new cyclobutane-platinum complex with antitumor activity. J Cancer Res Clin Oncology 116:439 (1990).CrossRefGoogle Scholar
  7. 7.
    H.H. Fiebig, D.P. Berger, K. Mross, W. Queiβer, P. Aulenbacher, and P. Hilgard. Lobaplatin (D-19466): Preclinical drug profile and results of the phase I study. Ann Oncol 3 (suppl) 143 (1992).CrossRefGoogle Scholar
  8. 8.
    H.H. Fiebig, D.P. Berger, W.A. Dengler, E. Wallbrecher, and B.R. Winterhalter. Combined in vitro/in vivo test procedure with human tumor xenografts. In: “Immunodeficient Mice in Oncology” H.H. Fiebig and D.P. Berger ed, Karger, Basel, Contrib Oncol 42:321 (1992).Google Scholar
  9. 9.
    A. Harstrick, C. Bokemeyer, M. Scharnofkse, G. Hapke, D. Reile, and HJ. Schmoll. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and-resistant human testicular, ovarian and gastric carcinoma cell lines. Cancer Chemoth and Pharmacol 33:43 (1993).CrossRefGoogle Scholar
  10. 10.
    Investigator’s Brochure Lobaplatin, ASTA Medica AG, Germany (1993).Google Scholar
  11. 11.
    H.H. Fiebig, K. Mross, H. Henß, D. Ludolph, F. Meyberg, P. Aulenbacher, and W. Queißer. Phase I Clinical Trial of Lobaplatin (D-19466) after intravenous bolus injection. Onkologie 17:142 (1994)CrossRefGoogle Scholar
  12. 12.
    K. Mross, F. Meyberg, H.H. Fiebig, K. Hamm, U. Hieber, P. Aulenbacher, and D.K. Hossfeld. Pharmacokinetic and pharmacodynamic study with lobaplatin (D-19466), a new platinum complex, after bolus administration. Onkologie 15:139 (1992).CrossRefGoogle Scholar
  13. 13.
    J.A. Gietema, H.J. Guchelaar, E.G.E. de Vries, P. Aulenbacher, D.T. Sleijfer, and N.H. Mulder. A phase I study of lobaplatin (D-19466) administered by 72 hours continuous Infusion. Anti-Cancer Drugs 4:51 (1993).CrossRefPubMedGoogle Scholar
  14. 14.
    J.A. Gietema, E.G.E. de Vries, D.T. Sleijfer, P.H.B. Willemse, H.J. Guchelaar, D.R.A. Uges, P. Aulenbacher, R. Voegeli, and N.H. Mulder. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br J Cancer 67:396 (1993).CrossRefPubMedGoogle Scholar
  15. 15.
    J.A. Gietema, G.J. Veldhuis, H.J. Guchelaar, P.H.B. Willemse, D.R.A. Uges, A. Cats, B. Boonstra, W.T.A. van der Graaf, D.T. Sleijfer, E.G.E. de Vries, and N.H. Mulder. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. BJC 71:1302 (1995).CrossRefPubMedGoogle Scholar
  16. 16.
    H.J. Schmoll, C.H. Könne, E. Papageorgiou, S. Luft, A. Harstrick, P. Bachmann, P. Hilgard, and U. Schubert. Single agent lobaplatin is active in patients with oesophageal squamous cell carcinoma: A phase II evaluation. Proc ASCO 14:201 (1995).Google Scholar
  17. 17.
    M. Degardin, M. De Forni, B. Chevallier, P. Kerbrat, M.A. Lentz, M. David, and H. Roché. Phase II study of Lobaplatin in head and neck cancer (HNC). Abstract 8. NCI-EORTC Symposium: 126 (1994).Google Scholar
  18. 18.
    C. Manegold, H.H. Fiebig, U. Gatzemeier, I. von Pawel, W. Queiβer, P. Bachmann, L. Edler, and P. Drings. Phase II Study of Lobaplatin in patients with advanced non small cell lung cancer. Onkologie 16, supplement 1, 13 (1993)Google Scholar
  19. 19.
    H.H. Fiebig, I. von Pawel, U. Gatzemeier, C. Manegold, L. Edler, K. Burk, P. Bachmann, W. Berdel. Phase II study of the platinum complex lobaplatin in patients with extensive small cell lung cancer after previous chemotherapy. Onkologie 16, supplement 1, 14 (1993)Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • H. H. Fiebig
    • 1
  1. 1.Department of Internal MedicineUniversity of FreiburgFreiburgGermany

Personalised recommendations